Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. The purchase adds to a recent string of multibillion-dollar deals. More: Neurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with
read moreWith a new, patient-friendly route of administration, Amgen may have found a way to increase demand for Tepezza. A phase 3 trial of patients with thyroid eye disease has shown that subcutaneous injection of Tepezza by way of an on-body
read moreEli Lilly has published a video about how medicines affect lives to mark its 150th anniversary and the arrival of college basketball stars in its home city. More: Eli Lilly takes the court with 150th anniversary campaign to catch Final
read moreWhere does pharma’s reshoring push stand today, and what comes next? Reshoring Institute Executive Director Rosemary Coates explains the industry’s unique advantage and the hurdles still in the way. More: An update on the pharma industry’s reshoring effort Source: fierce
read moreThe number of drugs in development has fallen for the first time since the mid-1990s, according to a Citeline report. While methodological changes may have affected the result, the dip highlights a period when drugmakers have trimmed their pipelines and
read moreThe U.S. will impose a 100% tariff on drug imports with some exceptions. Takeda plans to cut 634 jobs in the U.S. as part of its $1.26 billion savings plan. Eli Lilly deepened its relationship with AI drug-discovery expert Insilico
read more© 1994 - 2026 B.M. Pharmaceuticals